Galectin Therapeutics Inc.

GALT | NASDAQ

Price Alert Chart Builder DCF Calculator

$4.10

+$0.14 (+3.54%)

Sep 22, 2026, 9:44 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $260.79M

Enterprise Value $385.23M

Beta 0.35

Average Volume 557.55K

Shares Outstanding (Diluted) 65.88M

Shares Change YoY 3.83%

Institutional Ownership 21.19%

Exchange NASDAQ

ISIN US3632252025

Price Performance

Price Change 1M 6.5%

Price Change 3M 26.9%

Price Change 6M 35.1%

Price Change YTD -2.2%

Price Change 1Y -19.5%

Price Change 3Y 126.3%

Price Change 5Y -4.6%

1M CAGR (ann.) 14.8%

1Y CAGR (ann.) -14.7%

5Y CAGR (ann.) 1.1%

All-Time CAGR 0.2%

Valuation

PE Ratio -9.21

Forward PE N/A

PEG Ratio -0.24

Forward PEG 0.40

PS Ratio N/A

Forward PS 0.70

PB Ratio -1.91

P/FCF Ratio -16.41

P/Adj. FCF Ratio -14.31

P/OCF Ratio -16.50

EV/Sales N/A

EV/EBIT -27.89

EV/EBITDA -28.00

EV/FCF -24.24

Earnings Yield -10.9%

FCF Yield -6.1%

Adj. FCF Yield -7.0%

Financial Health

Net Debt $124.43M

Total Debt $137.7M

Cash & Short-Term Investments $13.27M

Total Assets $14.83M

Current Ratio 0.10

Quick Ratio 0.10

Debt / Equity Ratio -1.01

Debt / EBITDA -10.01

Debt / FCF -8.67

OCF / Debt -0.12

Interest Coverage -2.02

Altman Z-Score -55.32

Piotroski F-Score 3

Margins & Profitability

Gross Profit Margin 0.0%

Operating Profit Margin 0.0%

EBITDA Margin 0.0%

Net Profit Margin 0.0%

FCF Margin N/A

Adj. FCF Margin N/A

SBC / Revenue 0.0%

SBC Impact (per share) -14.7%

Returns

Return on Assets -187.8%

Return on Equity 21.5%

Return on Invested Capital -1613.8%

Return on Capital Employed 11.4%

Return on Tangible Assets -187.8%

Historical Growth (CAGR)

Revenue CAGR 3Y N/A

Revenue CAGR 5Y N/A

Revenue CAGR 10Y N/A

EPS CAGR 3Y 29.0%

EPS CAGR 5Y 9.7%

EPS CAGR 10Y -4.2%

FCF CAGR 3Y 30.1%

FCF CAGR 5Y 8.0%

FCF CAGR 10Y -8.9%

Analyst Forecasts

Analyst Rating Buy

Analyst Count 11

EPS Growth Next 3Y -37.2%

Revenue Growth Next 3Y N/A

Earnings Date Nov 12, 2026

EPS Estimate (next Q) -$0.05

EPS Growth Est (next Q) -61.5%

Revenue Est (next Q) N/A

Revenue Growth Est (next Q) N/A

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $11

Price Target Upside 177.8%

Cash Flow

Operating Cash Flow $-15.89M

Free Cash Flow $-15.89M

Adj. Free Cash Flow $-18.23M

FCF Per Share -$0.24

OCF Per Share -$0.24

OCF/S Ratio 0.0%

Income Statement

Revenue $0

Gross Profit $0

Operating Income $-15.62M

EBITDA $-13.76M

Net Income $-27.84M

EPS (Diluted) -$0.43

Revenue / Employee N/A

Profit / Employee $-3.09M

Employees 9